A Multicenter, Randomized, Phase 2 Study to Assess the Feasibility, Safety and Efficacy of OTO-104 Given by Intratympanic Administration in Subjects at Risk for Ototoxicity From Cisplatin Chemotherapy Regimens in the Treatment of Cancer

Trial Profile

A Multicenter, Randomized, Phase 2 Study to Assess the Feasibility, Safety and Efficacy of OTO-104 Given by Intratympanic Administration in Subjects at Risk for Ototoxicity From Cisplatin Chemotherapy Regimens in the Treatment of Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Hearing loss
  • Focus Therapeutic Use
  • Sponsors Otonomy
  • Most Recent Events

    • 16 Dec 2016 Status changed from planning to recruiting.
    • 03 Nov 2016 According to an Otonomy media release, this trial is expected to initiate in the fourth quarter of 2016.
    • 09 May 2016 This trial is expected to be initiated in the second half of 2016, according to an Otonomy media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top